NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

A team has identified an experimental molecule capable of "reprogramming" the brain's immune cells to restore part of their ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.

Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center for Cancer Biology and ...

Company has now raised $6 million since founding to advance mRNA-based therapeutics designed to turn tumor cells into immune-activating cellsSAN CARLOS, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- ...

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits ...

A new way of reprogramming our immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard to treat and devastating skin cancer, melanoma. The discovery demonstrates a ...

Cancer immunotherapy has advanced the field of medicine and cancer care. Specifically, immunotherapy refers to the targeted treatment of the immune system. Over the last few decades, immunotherapy has ...